Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001079973-25-000276
Filing Date
2025-02-14
Accepted
2025-02-14 17:04:12
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6180
  Complete submission text file 0001079973-25-000276.txt   8119
Mailing Address 3600 GREEN COURT SUITE 350 ANN ARBOR MI 48105
Business Address 3600 GREEN COURT SUITE 350 ANN ARBOR MI 48105 734-335-0468
ENDRA Life Sciences Inc. (Subject) CIK: 0001681682 (see all company filings)

EIN.: 260579295 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90044 | Film No.: 25630635
SIC: 3845 Electromedical & Electrotherapeutic Apparatus
(CF Office: 08 Industrial Applications and Services)

Mailing Address 161A SHEDDEN ROAD ONE ARTILLERY COURT P.O. BOX 10085 GRAND CAYMAN E9 KY1-1001
Business Address 161A SHEDDEN ROAD ONE ARTILLERY COURT P.O. BOX 10085 GRAND CAYMAN E9 KY1-1001 646-688-5654
L1 Capital Global Opportunities Master Fund, Ltd. (Filed by) CIK: 0001702202 (see all company filings)

EIN.: 981241877 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A